MAPT and Alzheimer disease: These data demonstrating mitigation of neuropathology were consistent with the ability of BPN-15606 to substantially reduce the levels of insoluble Aβ42 as well as insoluble total tau and pThr181 tau in the 3D human neural cell culture model of AD, suggesting that BPN-15606 reduced p-tau pathology and Aβ42 accumulation (Fig. 8).